Eli Lilly Sets Monday Deadline for 340B Hospitals to Share Claims Data
Eli Lilly has issued an ultimatum to certain 340B hospitals, demanding they share claims data by Monday to verify they are not obtaining duplicate drug discounts. The drugmaker claims some hospitals have refused to provide documentation showing compliance with 340B program rules that prohibit double-dipping on Medicaid rebates and discounted drug purchases. Hospitals are calling on federal authorities to intervene in the dispute. The conflict reflects ongoing tensions over 340B program integrity and manufacturer efforts to limit perceived abuse of the discount program.
Medicaid managed care organizations processing pharmacy claims need to track whether providers are billing for drugs already purchased at 340B discounts, as duplicate payments trigger rebate violations and federal compliance issues.
Pharmacy · Managed Care
You might also like